LD-2 disclosure · 3rd Quarter - Report
PFIZER INC.
via PFIZER INC.
Client
- Name
- PFIZER INC.
- Location
- District of Columbia · United States of America
Registrant
- Firm
- PFIZER INC.
- Description
- Biopharmaceuticals
- Location
- WASHINGTON, District of Columbia, United States of America
Lobbying activities
3 issuesHealth Issues
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
LobbyistsEMILY MUELLER · CATHERINE ROBINSON · FRANCISCO CARRILLO · MATTHEW STROIA · ms JENNIFER SWENSON WALTON · mrs ANGELA BOOTHE WILES
TargetedSENATE · HOUSE OF REPRESENTATIVES · Executive Office of the President (EOP) · Health & Human Services, Dept of (HHS)
Medicare/Medicaid
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform S 1702 - Access to Prescription Digital Therapeutics Act of 2025 Digital Therapeutics
LobbyistsEMILY MUELLER · FRANCISCO CARRILLO · mrs ANGELA BOOTHE WILES
TargetedSENATE
Trade (domestic/foreign)
International Supply Chain Global Access Most Favored Nation Policies Tariffs Non-Tariff Trade Barriers United States-Mexico-Canada Agreement (USMCA)